A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination.

Nicole G Campos, Douglas R Lowy, Silvia de Sanjosé, Mark Schiffman
{"title":"A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination.","authors":"Nicole G Campos, Douglas R Lowy, Silvia de Sanjosé, Mark Schiffman","doi":"10.1093/jncimonographs/lgae040","DOIUrl":null,"url":null,"abstract":"<p><p>One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited \"one screen\" campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if \"one dose, one screen\" is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":"2024 67","pages":"417-423"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgae040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited "one screen" campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if "one dose, one screen" is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对低资源环境的宫颈癌控制策略:补充一剂 HPV 疫苗接种的干预措施。
在资源匮乏的环境中,为青春期前儿童接种一剂预防性 HPV 疫苗可能会大大降低宫颈癌的死亡率,但在青春期前儿童中立即实现高覆盖率所带来的益处要在 20 到 40 年后才能实现。初次性行为后,预防性疫苗的效力会降低,而且目前旨在治疗现有人乳头瘤病毒感染或癌前病变的治疗干预候选方案还没有足够的证据证明可以广泛使用。不过,我们正在开发一种可行、可扩展、高质量的宫颈筛查方法,它可以预防数十万人的死亡,同时我们也在努力实现青少年群体一剂疫苗接种的高覆盖率。在资源较少的环境中开展有时间限制的 "一次筛查 "活动,可以补充同时为实现一剂疫苗接种的高覆盖率所做的努力。这种 "筛查--分流--治疗 "策略将针对筛查年龄段(即 25 至 49 岁)的高风险人群,使用低成本的精确 HPV 检测仪对自采样本进行一生一次的 HPV 检测;随后依靠扩展的基因分型和经过验证的自动视觉评估 (AVE) 深度学习算法进行分流,根据风险进行分层管理,为最有可能罹患癌症的人群提供治疗,而不会给医疗保健系统带来过重负担。HPV-AVE(PAVE)研究联盟已在 9 个国家证明了这种方法的早期疗效。我们估计,筛查--治疗--运动每避免一例死亡的成本与预防性疫苗接种的成本相近。如果 "一剂一筛 "能在高覆盖率的情况下实施并针对高风险人群,我们认为就不会对无处不在的实体筛查项目进行永久性投资。我们正在与国内利益相关者合作,努力确保可接受性、风险沟通和成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
0
期刊最新文献
Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study. Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination. Evaluating potential program cost savings with a single-dose HPV vaccination schedule: a modeling study. HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1